Browse BAG6

Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol Nucleus Secreted, exosome Note=Normally localized in cytosol and nucleus, it can also be released extracellularly, in exosomes, by tumor and myeloid dendritic cells.
Domain PF12057 Domain of unknown function (DUF3538)
PF00240 Ubiquitin family
Function

ATP-independent molecular chaperone preventing the aggregation of misfolded and hydrophobic patches-containing proteins (PubMed:21636303). Functions as part of a cytosolic protein quality control complex, the BAG6/BAT3 complex, which maintains these client proteins in a soluble state and participates to their proper delivery to the endoplasmic reticulum or alternatively can promote their sorting to the proteasome where they undergo degradation (PubMed:20516149, PubMed:21636303, PubMed:21743475, PubMed:28104892). The BAG6/BAT3 complex is involved in the post-translational delivery of tail-anchored/type II transmembrane proteins to the endoplasmic reticulum membrane. Recruited to ribosomes, it interacts with the transmembrane region of newly synthesized tail-anchored proteins and together with SGTA and ASNA1 mediates their delivery to the endoplasmic reticulum (PubMed:20516149, PubMed:20676083, PubMed:28104892). Client proteins that cannot be properly delivered to the endoplasmic reticulum are ubiquitinated by RNF126, an E3 ubiquitin-protein ligase associated with BAG6 and are sorted to the proteasome (PubMed:24981174, PubMed:28104892, PubMed:27193484). SGTA which prevents the recruitment of RNF126 to BAG6 may negatively regulate the ubiquitination and the proteasomal degradation of client proteins (PubMed:23129660, PubMed:25179605, PubMed:27193484). Similarly, the BAG6/BAT3 complex also functions as a sorting platform for proteins of the secretory pathway that are mislocalized to the cytosol either delivering them to the proteasome for degradation or to the endoplasmic reticulum (PubMed:21743475). The BAG6/BAT3 complex also plays a role in the endoplasmic reticulum-associated degradation (ERAD), a quality control mechanism that eliminates unwanted proteins of the endoplasmic reticulum through their retrotranslocation to the cytosol and their targeting to the proteasome. It maintains these retrotranslocated proteins in an unfolded yet soluble state condition in the cytosol to ensure their proper delivery to the proteasome (PubMed:21636303). BAG6 is also required for selective ubiquitin-mediated degradation of defective nascent chain polypeptides by the proteasome. In this context, it may participate to the production of antigenic peptides and play a role in antigen presentation in immune response (By similarity). BAG6 is also involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation. BAG6 may ensure the proper degradation of these proteins and thereby protects the endoplasmic reticulum from protein overload upon stress (PubMed:26565908). By inhibiting the polyubiquitination and subsequent proteasomal degradation of HSPA2 it may also play a role in the assembly of the synaptonemal complex during spermatogenesis (By similarity). Also positively regulates apoptosis by interacting with and stabilizing the proapoptotic factor AIFM1 (By similarity). By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway (PubMed:26692333). ; FUNCTION: Involved in DNA damage-induced apoptosis: following DNA damage, accumulates in the nucleus and forms a complex with p300/EP300, enhancing p300/EP300-mediated p53/TP53 acetylation leading to increase p53/TP53 transcriptional activity (PubMed:17403783). When nuclear, may also act as a component of some chromatin regulator complex that regulates histone 3 'Lys-4' dimethylation (H3K4me2) (PubMed:18765639). ; FUNCTION: Released extracellularly via exosomes, it is a ligand of the natural killer/NK cells receptor NCR3 and stimulates NK cells cytotoxicity. It may thereby trigger NK cells cytotoxicity against neighboring tumor cells and immature myeloid dendritic cells (DC). ; FUNCTION: Mediates ricin-induced apoptosis.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0007029 endoplasmic reticulum organization
GO:0007059 chromosome segregation
GO:0007126 meiotic nuclear division
GO:0007127 meiosis I
GO:0007129 synapsis
GO:0007130 synaptonemal complex assembly
GO:0007283 spermatogenesis
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0031647 regulation of protein stability
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0034976 response to endoplasmic reticulum stress
GO:0036503 ERAD pathway
GO:0036506 maintenance of unfolded protein
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043543 protein acylation
GO:0045048 protein insertion into ER membrane
GO:0045132 meiotic chromosome segregation
GO:0045143 homologous chromosome segregation
GO:0045732 positive regulation of protein catabolic process
GO:0045861 negative regulation of proteolysis
GO:0048232 male gamete generation
GO:0050821 protein stabilization
GO:0051205 protein insertion into membrane
GO:0051321 meiotic cell cycle
GO:0060541 respiratory system development
GO:0061136 regulation of proteasomal protein catabolic process
GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress
GO:0070192 chromosome organization involved in meiotic cell cycle
GO:0070193 synaptonemal complex organization
GO:0071816 tail-anchored membrane protein insertion into ER membrane
GO:0072001 renal system development
GO:0072331 signal transduction by p53 class mediator
GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator
GO:0072657 protein localization to membrane
GO:0090150 establishment of protein localization to membrane
GO:0097193 intrinsic apoptotic signaling pathway
GO:0098813 nuclear chromosome segregation
GO:1901799 negative regulation of proteasomal protein catabolic process
GO:1903046 meiotic cell cycle process
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903051 negative regulation of proteolysis involved in cellular protein catabolic process
GO:1903362 regulation of cellular protein catabolic process
GO:1903363 negative regulation of cellular protein catabolic process
GO:1904292 regulation of ERAD pathway
GO:1904294 positive regulation of ERAD pathway
GO:1904327 protein localization to cytosolic proteasome complex
GO:1904378 maintenance of unfolded protein involved in ERAD pathway
GO:1904379 protein localization to cytosolic proteasome complex involved in ERAD pathway
Molecular Function GO:0002020 protease binding
GO:0030544 Hsp70 protein binding
GO:0031072 heat shock protein binding
GO:0031593 polyubiquitin binding
GO:0031625 ubiquitin protein ligase binding
GO:0032182 ubiquitin-like protein binding
GO:0043021 ribonucleoprotein complex binding
GO:0043022 ribosome binding
GO:0043130 ubiquitin binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0051787 misfolded protein binding
GO:0070628 proteasome binding
GO:1990381 ubiquitin-specific protease binding
Cellular Component GO:0044445 cytosolic part
GO:0071818 BAT3 complex
GO:0072379 ER membrane insertion complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BAG6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BAG6 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23509156Chronic Lymphocytic LeukemiaInhibit immunity (NK cell infiltration)Soluble CLL plasma factors suppressed NK cell cytotoxicity and down-regulated the surface receptors CD16 and CD56 on NK cells of healthy donors. The inhibition of NK cell cytotoxicity was attributed to the soluble ligand BAG6/BAT3 that engages the activating receptor NKp30 expressed on NK cells.
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BAG6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BAG6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.240.358
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1180.94
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3250.79
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4170.138
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4280.873
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4050.907
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.150.723
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.20.924
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0960.967
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.090.969
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0870.98
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0790.194
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BAG6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BAG6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BAG6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BAG6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BAG6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BAG6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BAG6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBAG6
NameBCL2-associated athanogene 6
Aliases G3; D6S52E; BAT3; HLA-B associated transcript 3; BAG-6; BAG family molecular chaperone regulator 6; HLA-B as ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BAG6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.